Lexicon Pharmaceuticals (LXRX) Times Interest Earned (2010 - 2026)
Lexicon Pharmaceuticals (LXRX) posted quarterly Times Interest Earned of -$0.23 for Q1 2026, up 97.32% year-over-year from -$0.12 in Q1 2025, and up 96.82% quarter-over-quarter from -$7.28 in Q4 2025.
Powered by 
Analysis
Lexicon Pharmaceuticals (LXRX) Times Interest Earned (2010 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has reported Times Interest Earned for 17 consecutive years, with -$0.23 the latest figure, recorded in Q1 2026.
- In Q1 2026, Times Interest Earned rose 97.32% year-over-year to -$0.23; the TTM figure through Mar 2026 stood at -$5.63 (up 56.83% YoY), while the FY2025 annual figure was -$4.2, down 796.92% from the prior year.
- Times Interest Earned grew to -$0.23 in Q1 2026 per LXRX's latest filing, from -$7.28 in the prior quarter.
- Across five years, Times Interest Earned topped out at $6.76 in Q4 2022 and bottomed at -$212.55 in Q1 2022.
- Historically, Times Interest Earned has averaged -$20.87 across 5 years, with a median of -$8.49 in 2024.
- Annual changes were most pronounced in 2022 — Times Interest Earned soared 102.48% — and 2024, when it plunged 307.45%.
- Lexicon Pharmaceuticals' Times Interest Earned stood at $6.76 in 2022, then tumbled by 209.1% to -$7.38 in 2023, then decreased by 15.0% to -$8.49 in 2024, then climbed by 14.24% to -$7.28 in 2025, then soared by 96.82% to -$0.23 in 2026.
- Business Quant data shows LXRX's Times Interest Earned at -$0.23 in Q1 2026, -$7.28 in Q4 2025, and -$2.71 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Lexicon Pharmaceuticals | 978.15 Mn | 787.54 Mn | 653,000.00 | -10.17 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.17 |
| Mar 31, 2026 | -0.63 |
| Dec 31, 2025 | -7.28 |
| Sep 30, 2025 | -5.66 |
| Jun 30, 2025 | 1.61 |
| Mar 31, 2025 | -13.99 |
| Dec 31, 2024 | -8.49 |
| Sep 30, 2024 | -13.96 |
| Jun 30, 2024 | -25.04 |
| Mar 31, 2024 | -9.16 |
| Dec 31, 2023 | -8.62 |
| Sep 30, 2023 | -12.73 |
| Jun 30, 2023 | -22.57 |
| Mar 31, 2023 | -17.10 |
| Dec 31, 2022 | -27.45 |
| Sep 30, 2022 | -26.73 |
| Jun 30, 2022 | -34.15 |
| Mar 31, 2022 | -212.55 |
| Dec 31, 2021 | -85.86 |
| Sep 30, 2021 | -134.28 |